Last reviewed · How we verify
glargine + exenatide
glargine + exenatide is a Basal insulin + GLP-1 receptor agonist combination Small molecule drug developed by Huazhong University of Science and Technology. It is currently FDA-approved for Type 2 diabetes mellitus.
This combination pairs a long-acting basal insulin (glargine) with a GLP-1 receptor agonist (exenatide) to lower blood glucose through both insulin replacement and incretin-mimetic pathways.
This combination pairs a long-acting basal insulin (glargine) with a GLP-1 receptor agonist (exenatide) to lower blood glucose through both insulin replacement and incretin-mimetic pathways. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | glargine + exenatide |
|---|---|
| Sponsor | Huazhong University of Science and Technology |
| Drug class | Basal insulin + GLP-1 receptor agonist combination |
| Target | Insulin receptor (glargine); GLP-1 receptor (exenatide) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Glargine provides steady basal insulin coverage to suppress hepatic glucose production and lower fasting glucose. Exenatide stimulates insulin secretion in response to meals, slows gastric emptying, and promotes satiety, together achieving complementary glycemic control. The combination addresses both fasting and postprandial hyperglycemia in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Nausea
- Vomiting
- Injection site reactions
- Headache
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PHASE3)
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period (PHASE3)
- New Onset Type 1 Diabetes: Role of Exenatide (PHASE4)
- Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glargine + exenatide CI brief — competitive landscape report
- glargine + exenatide updates RSS · CI watch RSS
- Huazhong University of Science and Technology portfolio CI
Frequently asked questions about glargine + exenatide
What is glargine + exenatide?
How does glargine + exenatide work?
What is glargine + exenatide used for?
Who makes glargine + exenatide?
What drug class is glargine + exenatide in?
What development phase is glargine + exenatide in?
What are the side effects of glargine + exenatide?
What does glargine + exenatide target?
Related
- Drug class: All Basal insulin + GLP-1 receptor agonist combination drugs
- Target: All drugs targeting Insulin receptor (glargine); GLP-1 receptor (exenatide)
- Manufacturer: Huazhong University of Science and Technology — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing